Core Viewpoint - Vertical Aerospace Ltd. is under investigation for potential securities fraud and unlawful business practices following a significant disclosure in its annual report that raised doubts about its ability to continue as a going concern [1][3]. Financial Disclosure - On March 24, 2026, Vertical Aerospace filed its annual report for 2025, indicating limited cash and cash equivalents, recurring operational losses, and a dependency on raising additional capital, which suggests material uncertainty regarding its future viability [3]. - Following this disclosure, the company's stock price dropped by $0.64 per share, or 18.18%, closing at $2.88 per share on the same day [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors of Vertical Aerospace, focusing on whether the company and its officers or directors have engaged in securities fraud or other unlawful business practices [1].

Core Viewpoint - Sun Life U.S. continues to support the Roux Institute's Pre-Clinical Healthcare Gap Year Program, honoring the legacy of recently retired president Dan Fishbein, M.D., and aims to improve access to healthcare services in Maine [1][2][3]. Group 1: Program Overview - The Gap Year Program, launched in 2023, places recent college graduates in frontline healthcare roles, addressing staff shortages in hospitals, health clinics, and dental practices throughout Maine [1][3]. - Over 80 professionals have been placed in health service roles through the program, which has expanded its partnerships with medical and dental clinics [2][5]. - Nearly all participants express intent to pursue careers in healthcare after completing the program [3]. Group 2: Leadership and Impact - Dan Fishbein has been a key advocate for the Gap Year Program, aligning it with Sun Life's strategy to enhance healthcare access [2][3]. - Aileen Huang-Saad, director at the Roux Institute, emphasizes the program's role in increasing healthcare provider availability in rural and underserved areas, with hopes for similar initiatives in other states [5]. Group 3: Participant Experience - Program participant Jillian Fitzpatrick highlights the positive impact of the program on her confidence and career path as she transitions to dental school [4]. Group 4: Company Background - Sun Life is a leading international financial services organization with operations in multiple markets, including the U.S., Canada, and several Asian countries, managing total assets of C$1.60 trillion as of December 31, 2025 [7][8]. - Sun Life U.S. serves approximately 48 million Americans, providing a range of employee and government benefits [9].

Core Insights - The Asset Special Opportunities Fund IX has surpassed its original target of $2.5 billion, indicating a continued interest from investors in private credit [1] Group 1 - The fund's success reflects a strong appetite for private credit investments among certain investors [1]

Group 1 - The core focus of Crude Value Insights is on cash flow and companies that generate it, highlighting value and growth prospects in the oil and natural gas sector [1] - Subscribers benefit from a 50+ stock model account, which provides a comprehensive analysis of cash flow for exploration and production (E&P) firms [1] - The service includes live chat discussions about the sector, fostering a community for investors interested in oil and gas [1] Group 2 - A two-week free trial is available for new subscribers, encouraging engagement with the oil and gas investment community [2]

Core Viewpoint - The optimism expressed by Federal Reserve officials contrasts with a series of negative economic indicators, suggesting a potential disconnect between policy outlook and economic reality [1] Group 1 - Federal Reserve officials maintain a positive outlook on the economy despite recent gloomy signals [1] - Economic indicators have shown signs of weakness, raising concerns about the sustainability of growth [1] - The divergence between Fed optimism and economic data may impact future monetary policy decisions [1]

Core Insights - CPI Aerostructures, Inc. reported financial results for Q4 and full year 2025, highlighting challenges due to the A-10 Program termination but also significant contract wins in the Aerospace & Defense sector [3][4] - The company ended 2025 with a strong backlog of $505 million and successfully refinanced its debt, enhancing financial flexibility [5] Financial Performance - Q4 2025 revenue was $19.4 million, down from $21.8 million in Q4 2024; gross profit decreased to $3.9 million from $4.3 million, with a gross margin of 20.3% compared to 20.0% [8] - Full year 2025 revenue was $69.3 million, down from $81.1 million in 2024; gross profit fell to $10.6 million from $17.2 million, resulting in a gross margin of 15.2% [8] - Net loss for 2025 was $0.8 million compared to a net income of $3.3 million in 2024; earnings per share were ($0.07) compared to $0.26 [8] Operational Highlights - The company achieved significant milestones in support of critical defense priorities and secured new contracts from major clients including Raytheon and Lockheed Martin [4][5] - CPI Aero is recognized as a prime contractor to the U.S. Department of Defense and provides various services including engineering and program management [6] Debt and Financial Position - As of December 31, 2025, total debt was $18.4 million, an increase from $17.4 million in 2024; the company refinanced its debt with Western Alliance Bank, extending maturity to December 2030 [8][5] - Total assets increased to $75.2 million in 2025 from $68.0 million in 2024, while total liabilities rose to $49.4 million from $42.0 million [13][14]

Core Viewpoint - The Gabelli Equity Trust has updated the offering price of its Rights Offering to $5.00 per share and extended the expiration date to April 21, 2026 [1][2]. Group 1: Offering Details - The Subscription Price has been revised from $5.50 to $5.00 per share, reflecting current market conditions and investor feedback [1]. - The expiration date for the Rights Offering has been extended to April 21, 2026, at 5:00 PM Eastern Time [2]. - Ten Rights allow a shareholder to purchase one additional share of common stock, with an over-subscription privilege available for those who fully exercise their Primary Subscription Rights [3]. Group 2: Trading and Resubscription - The Rights will continue to trade on the New York Stock Exchange until April 20, 2026 [4]. - Subscriptions previously submitted through brokers will be cancelled due to the change in Subscription Price and expiration date, requiring shareholders to resubscribe at the new price [4]. Group 3: Company Overview - The Gabelli Equity Trust Inc. is a diversified, closed-end management investment company with total net assets of $2 billion, focusing on long-term capital growth [6].

Core Insights - The merger with Juniper Capital Advisors has significantly transformed PEDEVCO's scale, reserves, and earnings potential, expanding its operational footprint and nearly doubling its proved reserves [2][12]. Financial Performance Fourth Quarter 2025 - Average daily production increased by 143% to 5,310 Boe/d compared to Q4 2024 [3]. - Revenue rose by 118% to $23.1 million from $10.6 million in Q4 2024 [3][8]. - Adjusted EBITDA surged by 203% to approximately $15.4 million, up from $5.1 million in the prior year [3][21]. - The company reported a net loss of $8.5 million, a decline from a net income of $5.9 million in Q4 2024 [3][20]. Full-Year 2025 - Full-year average daily production was 2,494 Boe/d, a 36% increase from 1,835 Boe/d in 2024 [4][29]. - Total revenue for 2025 was $45.8 million, reflecting a 16% increase from $39.6 million in 2024 [4][22]. - Adjusted EBITDA for the year was $27.0 million, an 18% increase from $22.9 million in 2024 [4][28]. - The company reported a net loss of $10.4 million, compared to a net income of $12.3 million in 2024 [4][27]. Operational Highlights - The merger added approximately 310,000 net acres, significantly increasing the company's asset base in the Rockies [12]. - Year-end 2025 proved reserves totaled 32.1 million barrels of oil equivalent (MMBoe), a 77% increase from 18.1 MMBoe at year-end 2024 [12][40]. - The company participated in the drilling and completion of 36 gross development wells during 2025, with many beginning production in late 2025 [12]. Cost and Expense Analysis - Lease operating expenses (LOE) increased by 184% to $10.8 million in Q4 2025, primarily due to the acquired assets [15]. - General and administrative expenses rose by $9.8 million to $12.0 million, largely due to merger-related costs [16]. - Depreciation, depletion, amortization, and accretion (DD&A) increased by 32% to $6.8 million, driven by higher production volumes [17]. Guidance and Future Outlook - For 2026, the company anticipates net capital expenditures of $16 million to $20 million, with a focus on drilling and optimization projects [13]. - The guidance for adjusted EBITDA in 2026 is projected to be between $60 million and $70 million, based on average oil and gas prices [13][14].

Core Viewpoint - AT&T has signed a $2 billion deal to enhance the emergency cellular network FirstNet, which includes a $1 billion investment for improvements and $1 billion in cost savings through reduced rates [1][2]. Group 1: Contract Details - The contract awarded to AT&T is a 25-year agreement to build the federal emergency cellular network FirstNet, established following recommendations from a federal commission after the 9/11 attacks [2]. - FirstNet is utilized by 31,000 U.S. agencies, facilitating communication for first responders such as medical personnel, firefighters, and police officers [2]. Group 2: Government Involvement - The agreement was facilitated by an executive order from U.S. President Donald Trump in early 2025, which prompted federal agencies to review all contracts [3]. - AT&T's commitment to the public-private partnership is emphasized by the company's President of Public Sector, Wes Anderson [3].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by May 26, 2026 [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether ImmunityBio and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased or acquired ImmunityBio securities during the Class Period are encouraged to contact Pomerantz LLP to potentially become Lead Plaintiffs [2]. Group 2: FDA Warning - On March 24, 2026, a warning letter from the U.S. Food and Drug Administration (FDA) to ImmunityBio became public, stating that the company continued to promote its bladder-cancer drug, Anktiva, in a misleading manner despite previous warnings [4]. - The FDA's letter highlighted concerns regarding the accuracy of the company's promotions, including television advertisements and a podcast appearance [4]. Group 3: Stock Price Impact - Following the news of the FDA warning, ImmunityBio's stock price fell by $1.99 per share, representing a decline of 21.12%, closing at $7.41 per share on March 24, 2026 [5].